Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia

Gynecol Oncol. 2013 Aug;130(2):312-6. doi: 10.1016/j.ygyno.2013.05.017. Epub 2013 May 23.

Abstract

Objective: The purpose of this study was to identify the clinical factors associated with time to hCG remission among women with low-risk postmolar GTN.

Methods: This study included a non-concurrent cohort of 328 patients diagnosed with low-risk postmolar GTN according to FIGO 2002 criteria. Associations of time to hCG remission with history of prior mole, molar histology, time to persistence, use of D&C at persistence, presence of metastatic disease, FIGO score, hCG values at persistence, type of first line therapy and use of multiagent chemotherapy were investigated with both univariate and multivariate analyses.

Results: Overall median time to remission was 46 days. Ten percent of the patients required multi-agent chemotherapy to achieve hCG remission. Multivariate analysis incorporating the variables significant on univariate analysis confirmed that complete molar histology (HR 1.45), metastatic disease (HR 1.66), use of multi-agent therapy (HR 2.00) and FIGO score (HR 1.82) were associated with longer time to remission. There was a linear relationship between FIGO score and time to hCG remission. Each 1-point increment in FIGO score was associated with an average 17-day increase in hCG remission time (95% CI: 12.5-21.6).

Conclusions: Complete mole histology prior to GTN, presence of metastatic disease, use of multi-agent therapy and higher FIGO score were independent factors associated with longer time to hCG remission in low-risk GTN. Identifying the prognostic factors associated with time to remission and effective counseling may help improve treatment planning and reduce anxiety in patients and their families.

Keywords: Chemotherapy; Low-risk gestational trophoblastic neoplasia; Prognostic factors; hCG remission.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Chorionic Gonadotropin / blood*
  • Female
  • Gestational Trophoblastic Disease / blood
  • Gestational Trophoblastic Disease / drug therapy
  • Gestational Trophoblastic Disease / pathology*
  • Humans
  • Middle Aged
  • Pregnancy
  • Prognosis
  • Risk
  • Time Factors

Substances

  • Chorionic Gonadotropin